Streetbeat News

Earnings

CARA

Cara Therapeutics (NASDAQ:CARA) reported Q4 earnings with an EPS of $-0.59, missing estimates by -44.0% and a revenue decrease of $257 thousand from the previous year. The company's past earnings performance shows a pattern of not meeting EPS estimates, which previously led to a 7% drop in share price.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 9:05 pm

CARA

Cara Therapeutics (NASDAQ:CARA) reported Q4 2023 adjusted EPS of $(0.590), missing the $(0.410) estimate, and sales of $3.000M, missing the $9.421M estimate. This represents a 8.00% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 9:02 pm

APGE

Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotech company, announced it will report interim results from its Phase 1 APG777 healthy volunteer trial for atopic dermatitis and other inflammatory diseases on March 5, 2024. The company will host a conference call and webcast at 7:00am ET to discuss the results. The webcast will be accessible on Apogee's Investor Relations page.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 9:02 pm

NEWT

NewtekOne (NASDAQ:NEWT) is scheduled to release its quarterly earnings report on March 5, 2024, with an expected EPS of $0.58. Investors are hopeful for a beat on this estimate and positive future guidance. Historically, NewtekOne's stock price has been sensitive to earnings performance and guidance. Despite beating EPS estimates in the past, the stock experienced mixed price reactions. Currently, shares are trading at $11.29, reflecting a 25.99% decline over the last year, indicating investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 9:01 pm

XLE

OPEC+ extends its voluntary cut of 2.2 million barrels per day through Q2, with Russia announcing an additional cut of 471,000 barrels per day. This move aims to shore up oil prices amid weak global demand and uncertainty around China's reopening. The market has already priced in these events, with U.S. crude hovering around $80. The focus shifts to the EIA Weekly Petroleum Status Report, indicating a record U.S. production but low utilization rates, leading to a build-up in crude inventories. This dynamic is seen as bearish for crude prices but may stabilize as refinery maintenance concludes. Crude oil net long speculative positioning has increased, signaling a bullish outlook in the near term despite macroeconomic and geopolitical risks. Technical analysis suggests a bullish trend for crude, with significant resistance levels ahead. The Energy Select Sector SPDR Fund (XLE) indicates crude is relatively cheap compared to energy stocks within the index.

Portfolio Pulse from Kevin Green

March 04, 2024 | 8:18 pm

TXN

17 financial analysts have provided mixed evaluations of Texas Instruments (NASDAQ:TXN) over the past three months, with a current average 12-month price target of $171.65, up 1.92% from the previous target. The ratings range from bullish to indifferent, with a notable shift towards a more cautious stance in the last 30 days. Texas Instruments, a leading semiconductor manufacturer, faces challenges with a -12.7% revenue decline and a high debt-to-equity ratio, despite strong profitability indicators like net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 8:02 pm

MGNX

Analysts have updated their ratings and price targets for Macrogenics (NASDAQ:MGNX), showing a mix of bullish and bearish sentiments. The average 12-month price target has increased by 69.81% to $18.00. Recent upgrades by analysts from BTIG, Barclays, HC Wainwright & Co., JMP Securities, and Citigroup reflect positive adjustments in their outlooks based on Macrogenics's performance and market conditions. Macrogenics, a biotech company focusing on cancer therapeutics, faces revenue challenges but has strong financial indicators like net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 8:01 pm

NIO

TSLA

NIO Inc (NYSE:NIO) shares hit new 52-week lows amid expectations of a Q4 loss, analyst downgrades, and a decrease in February vehicle deliveries. The EV industry faces headwinds, impacting companies like NIO and Tesla (NASDAQ:TSLA), with Tesla's China sales also declining significantly.

Portfolio Pulse from Adam Eckert

March 04, 2024 | 8:01 pm

VLO

Valero Energy (NYSE:VLO) has seen unusual options activity, with an equal mix of bullish and bearish trades among investors. Significant trading volume has been observed, with a focus on strike prices between $100.0 and $200.0. The company, a major independent refiner, has a current stock price of $143.25, slightly down with potential overbought indicators. The next earnings report is expected in 52 days.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:16 pm

RNGR

Ranger Energy Services (NYSE:RNGR) is set to release its quarterly earnings report on 2024-03-05, with analysts estimating an EPS of $0.29. Historical performance shows mixed results with both misses and beats in past quarters. Shares are currently trading at $10.7, down 7.09% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm